CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
4d Molecular Therapeutics Inc   (FDMT)
Other Ticker:  
 

4d Molecular Therapeutics Inc 's Quick Ratio

FDMT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Quick Ratio fell to 17.6 below 4d Molecular Therapeutics Inc average.

Within Biotechnology & Pharmaceuticals industry 14 other companies have achieved higher Quick Ratio than 4d Molecular Therapeutics Inc in third quarter 2023. While Quick Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 121 to 142.

Explain Quick Ratio?
How much Cash & cash equivalents FDMT´s has?
What are FDMT´s Current Liabilities?


FDMT Quick Ratio (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change 33.91 % -4.06 % -6.72 % -3.72 % 19.26 %
Y / Y Cash & cash equivalent Change 40.38 % 28.73 % -15.12 % -13.81 % 40.85 %
Quick Ratio MRQ 17.6 22.57 17.77 13.58 16.79
FDMT's Total Ranking # 142 # 121 # 181 # 156 # 231
Seq. Current Liabilities Change 32.1 % 21.91 % -28.31 % 15.98 % -5.35 %
Seq. Cash & cash equivalent Change 3 % 54.82 % -6.13 % -6.22 % -5.55 %

New: More FDMT's historic Quick Ratios >>


Quick Ratio third quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 15
Healthcare Sector # 67
Overall Market # 142


Quick Ratio Statistics
High Average Low
24.7 17.83 13.58
(Jun 30 2021)   (Dec 31 2022)




Financial Statements
4d Molecular Therapeutics Inc 's Current Liabilities $ 18 Millions Visit FDMT's Balance sheet
4d Molecular Therapeutics Inc 's Cash & cash equivalent $ 320 Millions Visit FDMT's Balance sheet
Source of FDMT's Sales Visit FDMT's Sales by Geography


Cumulative 4d Molecular Therapeutics Inc 's Quick Ratio

FDMT's Quick Ratio for the trailling 12 Months

FDMT Quick Ratio

 (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth 33.91 % -4.06 % -6.72 % -3.72 % 19.26 %
Y / Y Cash & cash equivalent TTM Growth 40.38 % 28.73 % -15.12 % -13.81 % 40.85 %
Quick Ratio TTM 17.72 17.53 16.08 16.49 16.92
Total Ranking TTM # 2770 # 2910 # 2966 # 1701 # 159
Seq. Current Liabilities TTM Growth 32.1 % 21.91 % -28.31 % 15.98 % -5.35 %
Seq. Cash & cash equivalent TTM Growth 3 % 54.82 % -6.13 % -6.22 % -5.55 %

Quick ratio ranking by company, industry and sector >> Back to FDMT Financial Strength Comparisons >> Go to Compare FDMT Quick Ratio to its Competitors

On the trailing twelve months basis FDMT Cash & cash equivalent soared by 40.38 % in III Quarter 2023 year on year, faster than Current Liabilities, this led to increase in in 4d Molecular Therapeutics Inc 's Quick Ratio to 17.72, above FDMT average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 158 other companies have achieved higher Quick Ratio than 4d Molecular Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 2770, from total ranking during the twelve months ending second quarter 2023 at 2910.

Explain Quick Ratio?
How much Cash & cash equivalents FDMT´s has?
What are FDMT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 159
Healthcare Sector # 913
Within the Market # 2770


trailing twelve months Quick Ratio Statistics
High Average Low
18.15 16.1 8.55
(Sep 30 2021)   (Mar 31 2021)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Acumen Pharmaceuticals Inc   35.33 $ 215.434  Millions$ 6.098  Millions
Vaxcyte Inc   33.62 $ 1,265.684  Millions$ 37.650  Millions
Creative Medical Technology Holdings Inc   29.42 $ 11.974  Millions$ 0.407  Millions
Revolution Medicines Inc   27.45 $ 813.195  Millions$ 29.627  Millions
Cortexyme Inc   27.34 $ 61.593  Millions$ 2.253  Millions
Apogee Therapeutics inc   24.62 $ 422.854  Millions$ 17.178  Millions
Intensity Therapeutics Inc   21.61 $ 15.649  Millions$ 0.724  Millions
Cullinan Oncology Inc   21.30 $ 466.430  Millions$ 21.897  Millions
Krystal Biotech Inc   20.38 $ 562.069  Millions$ 27.583  Millions
Prokidney Corp  19.51 $ 396.334  Millions$ 20.311  Millions
Graphite Bio Inc   18.66 $ 233.986  Millions$ 12.537  Millions
Tourmaline Bio Inc   18.14 $ 147.024  Millions$ 8.105  Millions
Compass Therapeutics Inc   17.94 $ 163.703  Millions$ 9.124  Millions
Avrobio Inc   17.90 $ 105.842  Millions$ 5.912  Millions
4d Molecular Therapeutics Inc   17.60 $ 319.664  Millions$ 18.163  Millions
Icosavax Inc   17.59 $ 229.206  Millions$ 13.030  Millions
Neumora Therapeutics Inc   17.50 $ 509.565  Millions$ 29.123  Millions
Hillevax Inc   17.11 $ 324.410  Millions$ 18.958  Millions
Fusion Pharmaceuticals Inc   16.92 $ 191.348  Millions$ 11.312  Millions
Crispr Therapeutics Ag  15.64 $ 1,739.826  Millions$ 111.234  Millions
Denali Therapeutics Inc   15.58 $ 1,109.256  Millions$ 71.180  Millions
Cabaletta Bio Inc   15.49 $ 164.391  Millions$ 10.616  Millions
Voyager Therapeutics Inc   14.51 $ 252.936  Millions$ 17.427  Millions
Pharmacyte Biotech Inc   14.01 $ 73.425  Millions$ 5.240  Millions
Iteos Therapeutics Inc   13.82 $ 599.027  Millions$ 43.349  Millions
Caribou Biosciences Inc   13.78 $ 338.488  Millions$ 24.572  Millions
Vor Biopharma Inc   13.75 $ 160.098  Millions$ 11.645  Millions
Aura Biosciences Inc   13.68 $ 149.076  Millions$ 10.894  Millions
Vigil Neuroscience Inc   13.18 $ 133.643  Millions$ 10.142  Millions
Anavex Life Sciences Corp   13.00 $ 151.024  Millions$ 11.617  Millions

Date modified: 2023-11-12T11:21:21+00:00



Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com